Publications 2024

Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW (2024)
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891

Kared H, Jyssum I, Alirezaylavasani A, Egner IM, The Tran T, Tietze L, Lund KP, Tveter AT, Provan SA, Ørbo H, Haavardsholm EA, Vaage JT, Jørgensen K, Syversen SW, Lund-Johansen F, Goll GL, Munthe LA (2024)
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
Front Immunol, 15, 1296273
DOI 10.3389/fimmu.2024.1296273, PubMed 38455062

Karlsen TH, Kaasen Jørgensen K, Bergquist A (2024)
Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Hepatology (in press)
DOI 10.1097/HEP.0000000000001172, PubMed 39585345

Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F et al. (2024)
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
EBioMedicine, 108, 105317
DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039

Ørbo HS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Christensen IE, Mjaaland S, Kvien TK, Grødeland G, Kro GB, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Goll GL, Jørgensen KK, Syversen SW (2024)
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
RMD Open, 10 (2)
DOI 10.1136/rmdopen-2023-003545, PubMed 38599653

Publications 2023

Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW (2023)
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323

Gui W, Hole MJ, Molinaro A, Edlund K, Jørgensen KK, Su H, Begher-Tibbe B, Gaßler N, Schneider CV, Muthukumarasamy U, Mohs A, Liao L, Jaeger J, Mertens CJ, Bergheim I, Strowig T, Hengstler JG, Hov JR, Marschall HU, Trautwein C, Schneider KM (2023)
Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis
Nat Commun, 14 (1), 3304
DOI 10.1038/s41467-023-38840-8, PubMed 37280200

Haukeland JW, Vesterhus MN, Jørgensen KK, Frigstad SO, Karlsen TH (2023)
[The FIB-4 test as a decision-making tool]
Tidsskr Nor Laegeforen, 143 (5)
DOI 10.4045/tidsskr.23.0176, PubMed 36987901

Helgadottir H, Folseraas T, Kemmerich G, Aabakken L, Jørgensen KK, Vesterhus M (2023)
[Primary sclerosing cholangitis]
Tidsskr Nor Laegeforen, 143 (17)
DOI 10.4045/tidsskr.23.0156, PubMed 37987062

Hole MJ, Jørgensen KK, Holm K, Braadland PR, Meyer-Myklestad MH, Medhus AW, Reikvam DH, Götz A, Grzyb K, Boberg KM, Karlsen TH, Kummen M, Hov JR (2023)
A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation
Hepatology, 77 (3), 715-728
DOI 10.1002/hep.32773, PubMed 36056902

Hole MJ, Jørgensen KK, Holm K, Braadland PR, Meyer-Myklestad MH, Medhus AW, Reikvam DH, Götz A, Grzyb K, Boberg KM, Karlsen TH, Kummen M, Hov JR (2023)
Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
Hepatology, 77 (6), E188-E189
DOI 10.1097/HEP.0000000000000340, PubMed 36815351

Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ (2023)
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656

Solitano V, Facciorusso A, McGovern DPB, Nguyen T, Colman RJ, Zou L, Boland BS, Syversen SW, Jørgensen KK, Ma C, Armuzzi A, Wilson A, Jairath V, Singh S (2023)
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis
Clin Gastroenterol Hepatol, 21 (12), 3019-3029.e5
DOI 10.1016/j.cgh.2023.03.044, PubMed 37061107

Wolf AS, Ravussin A, König M, Øverås MH, Solum G, Kjønstad IF, Chopra A, Holmøy T, Harbo HF, Syversen SW, Jørgensen KK, Høgestøl EA, Vaage JT, Celius EG, Lund-Johansen F, Munthe LA, Nygaard GO, Mjaaland S (2023)
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
JCI Insight, 8 (12)
DOI 10.1172/jci.insight.165111, PubMed 37159281

Publications 2022

Bergquist A, Weismüller TJ, Levy C, Rupp C, Joshi D, Nayagam JS, Montano-Loza AJ, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby IF, Wiestler M, Wedemeyer H, Zhou T, Strassburg CP, Rigopoulou E, Dalekos G, Narasimman M, Verhelst X, Degroote H, Vesterhus M et al. (2022)
Impact on follow-up strategies in patients with primary sclerosing cholangitis
Liver Int, 43 (1), 127-138
DOI 10.1111/liv.15286, PubMed 35535655

Bjørlykke KH, Jahnsen J, Brynskov J, Molander P, Eberhardson M, Davidsdottir LG, Sipponen T, Hjortswang H, Goll GL, Syversen SW, Langholz E, Jørgensen KK, Steenholdt C (2022)
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
Scand J Gastroenterol, 58 (1), 25-33
DOI 10.1080/00365521.2022.2108684, PubMed 35996928

Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK (2022)
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Lancet Rheumatol, 5 (1), e36-e46
DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604

Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW (2022)
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981

Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA (2022)
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
BMC Med, 20 (1), 378
DOI 10.1186/s12916-022-02587-8, PubMed 36199139

Nguyen NH, Solitano V, Vuyyuru SK, MacDonald JK, Syversen SW, Jørgensen KK, Crowley E, Ma C, Jairath V, Singh S (2022)
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Gastroenterology, 163 (4), 937-949.e2
DOI 10.1053/j.gastro.2022.06.052, PubMed 35753383

Singh Y, Jons WA, Eaton JE, Vesterhus M, Karlsen T, Bjoerk I, Abildgaard A, Jorgensen KK, Folseraas T, Little D, Gulamhusein AF, Petrovic K, Negard A, Conte GM, Sobek JD, Jagtap J, Venkatesh SK, Gores GJ, LaRusso NF, Lazaridis KN, Erickson BJ (2022)
Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis
Eur Radiol Exp, 6 (1), 58
DOI 10.1186/s41747-022-00312-x, PubMed 36396865

Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL (2022)
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002417, PubMed 36328399

Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL (2022)
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355

Vesterhus M, Jørgensen KK, Frigstad SO, Haukeland JW, Karlsen TH (2022)
[We need a new strategy for liver disease]
Tidsskr Nor Laegeforen, 142 (3)
DOI 10.4045/tidsskr.21.0892, PubMed 35170917

Publications 2021

Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, Jørgensen KK, Jahnsen J, Kro GB, Warren DJ, Vaage EB, Kvien TK, Nissen-Meyer LH, Anderson AM, Grødeland G, Haavardsholm EA, Vaage JT, Mjaaland S, Syversen SW, Lund-Johansen F, Munthe LA, Goll GL (2021)
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Lancet Rheumatol, 4 (3), e177-e187
DOI 10.1016/S2665-9913(21)00394-5, PubMed 34977602

Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876

Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077

Vesterhus M, Wiencke K, Haukeland JW, Frigstad SO, Karlsen LN, Jørgensen KK, Folseraas T (2021)
[Diagnosis and treatment of autoimmune hepatitis]
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.20.1045, PubMed 34182737

Publications 2020

Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, Lannerstedt H, Midgard H (2020)
Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
PLoS One, 15 (3), e0230263
DOI 10.1371/journal.pone.0230263, PubMed 32163489

Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F et al. (2020)
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151

Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ et al. (2020)
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7, PubMed 32965617

Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007

Publications 2019

Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G et al. (2019)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274

Publications 2018

Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E (2018)
Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease
Hepatol Commun, 2 (8), 956-967
DOI 10.1002/hep4.1200, PubMed 30094406

Lindström L, Jørgensen KK, Boberg KM, Castedal M, Rasmussen A, Rostved AA, Isoniemi H, Bottai M, Bergquist A (2018)
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study
Scand J Gastroenterol, 53 (3), 297-304
DOI 10.1080/00365521.2017.1421705, PubMed 29301479

Publications 2017

Jahnsen J, Kaasen Jørgensen K (2017)
Experience with Biosimilar Infliximab (Remsima®) in Norway
Dig Dis, 35 (1-2), 83-90
DOI 10.1159/000449088, PubMed 28147374

Jørgensen KK, Lundin KE, Olsen IC, Kvien TK, Jahnsen J (2017)
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Lancet, 390 (10111), 2436
DOI 10.1016/S0140-6736(17)32463-7, PubMed 29208304

Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, NOR-SWITCH study group (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Lancet, 389 (10086), 2304-2316
DOI 10.1016/S0140-6736(17)30068-5, PubMed 28502609

Publications 2016

Henriksen EK, Jørgensen KK, Kaveh F, Holm K, Hamm D, Olweus J, Melum E, Chung BK, Eide TJ, Lundin KE, Boberg KM, Karlsen TH, Hirschfield GM, Liaskou E (2016)
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
J Hepatol, 66 (1), 116-122
DOI 10.1016/j.jhep.2016.09.002, PubMed 27647428

Jørgensen SF, Reims HM, Frydenlund D, Holm K, Paulsen V, Michelsen AE, Jørgensen KK, Osnes LT, Bratlie J, Eide TJ, Dahl CP, Holter E, Tronstad RR, Hanevik K, Brattbakk HR, Kaveh F, Fiskerstrand T, Kran AB, Ueland T, Karlsen TH, Aukrust P, Lundin KE, Fevang B (2016)
A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency
Am J Gastroenterol, 111 (10), 1467-1475
DOI 10.1038/ajg.2016.329, PubMed 27527747

Zenouzi R, Weismüller TJ, Jørgensen KK, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen TH, Boberg KM, Manns MP, Lohse AW, Schramm C (2016)
No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 14 (12), 1806-1812
DOI 10.1016/j.cgh.2016.07.032, PubMed 27521513

Publications 2015

Kevans D, Tyler AD, Holm K, Jørgensen KK, Vatn MH, Karlsen TH, Kaplan GG, Eksteen B, Gevers D, Hov JR, Silverberg MS (2015)
Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis
J Crohns Colitis, 10 (3), 330-7
DOI 10.1093/ecco-jcc/jjv204, PubMed 26526357

Publications 2013

Block M, Jørgensen KK, Oresland T, Lindholm E, Grzyb K, Cvancarova M, Vatn MH, Boberg KM, Börjesson L (2013)
Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis - what next?
J Crohns Colitis, 8 (5), 421-30
DOI 10.1016/j.crohns.2013.10.008, PubMed 24239402

Jørgensen KK, Lindström L, Cvancarova M, Karlsen TH, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM (2013)
Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease
Clin Gastroenterol Hepatol, 11 (5), 517-23
DOI 10.1016/j.cgh.2012.12.027, PubMed 23333218

Publications 2012

Jørgensen KK, Lindström L, Cvancarova M, Castedal M, Friman S, Schrumpf E, Foss A, Isoniemi H, Nordin A, Holte K, Rasmussen A, Bergquist A, Vatn MH, Boberg KM (2012)
Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study
Scand J Gastroenterol, 47 (8-9), 1021-9
DOI 10.3109/00365521.2012.685754, PubMed 22577871

Publications 2011

Jørgensen KK, Grzyb K, Lundin KE, Clausen OP, Aamodt G, Schrumpf E, Vatn MH, Boberg KM (2011)
Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients
Inflamm Bowel Dis, 18 (3), 536-45
DOI 10.1002/ibd.21699, PubMed 21456044

Publications 2010

Ricanek P, Lothe SM, Szpinda I, Jorde AT, Brackmann S, Perminow G, Jørgensen KK, Rydning A, Vatn MH, Tønjum T, IBSEN II study group (2010)
Paucity of mycobacteria in mucosal bowel biopsies from adults and children with early inflammatory bowel disease
J Crohns Colitis, 4 (5), 561-6
DOI 10.1016/j.crohns.2010.05.003, PubMed 21122560